Navigation Links
Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
Date:1/22/2013

NEWTON, Mass., Jan. 22, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, has announced a financing arrangement with Schooner Capital, a Boston-based investment firm.  The agreement provides Topokine with immediate capital and the ability to draw additional capital to advance the Company's pipeline, including XAF5 Gel, a clinical-stage skin cream for local reduction of excess subcutaneous fat.  Specific terms were not disclosed.

"We are delighted to partner with Schooner Capital," said Murat Kalayoglu, MD, PhD, Topokine President and CEO.  "Schooner's long-term commitment allows us to invest not only in the development of XAF5 Gel, but also other drugs in our pipeline."

"Topokine is generating impressive results and intellectual property at a rapid pace," said Ted Henderson , a Managing Director at Schooner Capital.  "We are committed to seeing Topokine's products get to market, whether by organic growth or with a best-in-class Pharmaceutical partner."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About Schooner Capital

Founded in 1971, Schooner Capital is a Boston-based private investment firm.  The firm approaches all investments with a long-term perspective and invests in private companies across stage and sector, with a focus on quality of management, unit economics, and long-term growth prospects.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are based on current beliefs and expectations, but actual results may differ.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., 1.000.000.0000, murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
2. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
3. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
4. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
5. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
6. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
7. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
8. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
9. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Echo Therapeutics Announces Proposed Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):